P2RY12 and coronary artery disorder: Rigorous inclusion and exclusion criteria were set to ensure the eligibility and relevance of studies, focusing on patients with coronary artery disease, novel P2Y12 inhibitors, comparison with clopidogrel, and efficacy and safety outcomes.